SureTrader Advertisement PRTC
Home > Boards > Free Zone > User's Groups > Mohacsy's Safe Portfolio Member Forum

Orphan Drug Status doesn't assure FDA approval of

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
n4807g Member Profile
Member Level 
Followed By 38
Posts 28,577
Boards Moderated 0
Alias Born 07/08/03
160x600 placeholder
Arcelormittal Narrows Losses, Cautions On China
Steel giant ArcelorMittal narrowed its net loss in the first quarter and forecast improved earnings to come as steel prices begin to recover, but cautioned that excess steel capacity in China still remains a concern.
More Top Equities Stories Of The Day
Real Estate for Autonomous Car Facilities Gains Movement in Silicon Valley
Endo Cuts Annual Guidance on Impairment Charge
ADRs End Mostly Lower; Royal Dutch Shell Declines
Amazon Partners with Atlas Air Worldwide for Cargo Services -- 2nd Update
Bats Profit Doubles in First Earnings Report Since Going Public
Mining Giants Hit by Brazil Suit -- WSJ
Merck Revenue Falls on Generic Competition
Rio Tinto Announces Latest Stage in Oyu Tolgoi Project
n4807g Member Level  Monday, 04/23/12 12:16:00 PM
Re: FullBoogie post# 60301
Post # of 72478 
Orphan Drug Status doesn't assure FDA approval of the compound being evaluated, it confers certain marketing advantages and tax credits should the drug be approved.

Like most small biotechs CYTR will succeed or fail on the technology they employ. In CYTR's case the delivery system. The near term future of INNO-206 will be clear when they report interim findings of their ongoing 2b trial.

Like all biotechs this is a speculative investment, but I've watched many companies with similar strategies do well. The preliminary data look promising (no guarantee) but as I said in my previous post Abraxane uses Albumin as the entry vehicle in tumors and CYTR uses the same concept.

SureTrader
Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist